- 現金殖利率: N/A、總殖利率: 0、5年平均現金配發率: N/A
- 要留意資產負債表的未分配盈餘和配息能力, 如果為負值, 可能會無法發放股利
- 股利有2個稅要支出, 分別是綜合所得稅和健保補充保費(單筆股利達2萬元以上, 課2.11%)
| EPS YoY | 現金股利 YoY | 股票股利 YoY | 現金配發率 YoY | 股票配發率 YoY | 全部配發率 YoY | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 (5) | -0.23 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| 2024 (4) | -4.12 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| 2023 (3) | -3.94 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| EPS QoQ YoY | 本業EPS QoQ YoY | 累計EPS QoQ YoY | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 26Q1 (8) | -0.07 | -240.0 | 36.36 | -0.16 | -100.0 | -6.67 | -0.07 | 69.57 | 36.36 |
| 25Q4 (7) | 0.05 | 600.0 | 112.82 | -0.08 | 38.46 | 0.0 | -0.23 | 17.86 | 94.42 |
| 25Q3 (6) | -0.01 | 93.75 | 98.99 | -0.13 | -30.0 | -30.0 | -0.28 | 0.0 | 92.67 |
| 25Q2 (5) | -0.16 | -45.45 | 87.4 | -0.10 | 33.33 | 23.08 | -0.28 | -154.55 | 90.11 |
| 25Q1 (4) | -0.11 | 71.79 | 0.0 | -0.15 | -87.5 | 0.0 | -0.11 | 97.33 | 0.0 |
| 24Q4 (3) | -0.39 | 60.61 | 0.0 | -0.08 | 20.0 | 0.0 | -4.12 | -7.85 | 0.0 |
| 24Q3 (2) | -0.99 | 22.05 | 0.0 | -0.10 | 23.08 | 0.0 | -3.82 | -34.98 | 0.0 |
| 24Q2 (1) | -1.27 | 0.0 | 0.0 | -0.13 | 0.0 | 0.0 | -2.83 | 0.0 | 0.0 |
| 年/月 | 營收 | 月增率(%) | 去年同期年增率(%) | 累計營收 | 累計營收年增率(%) | 近三月累計營收 | 存貨銷售比 | 自結稅前EPS | 自結稅前累計EPS | 備註(年增率變動50%需說明原因) |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026/4 | 0.04 | 178200.0 | -70.79 | 0.04 | -70.78 | 0.04 | N/A | 本公司新藥仍在研發階段，目前營收來源為健康食品銷售，僅於出貨予代理商之月份認列營收，因並非每月固定出貨致使營收變動。 | ||
| 2026/3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1500.0 | 本公司新藥仍在研發階段，目前營收來源為健康食品銷售，僅於出貨予代理商之月份認列營收，因並非每月固定出貨致使營收變動。 | ||
| 2026/2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0 | 本公司新藥仍在研發階段，目前營收來源為健康食品銷售，僅於出貨予代理商之月份認列營收，因並非每月固定出貨致使營收變動。 | ||
| 2026/1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.12 | 0.24 | 本公司新藥仍在研發階段，目前營收來源為健康食品銷售，僅於出貨予代理商之月份認列營收，因並非每月固定出貨致使營收變動。 | ||
| 2025/12 | 0.0 | -100.0 | 0.0 | 0.38 | -14.39 | 0.12 | 0.24 | 本公司新藥仍在研發階段，目前營收來源為健康食品銷售，僅於出貨予代理商之月份認列營收，因並非每月固定出貨致使營收變動。 | ||
| 2025/11 | 0.12 | 0.0 | 32.54 | 0.38 | -14.39 | 0.12 | 0.24 | 本公司新藥仍在研發階段，目前營收來源為健康食品銷售，僅於出貨予代理商之月份認列營收，因並非每月固定出貨致使營收變動。 | ||
| 2025/10 | 0.0 | 0.0 | 0.0 | 0.26 | -26.92 | 0.06 | 0.54 | 本公司新藥仍在研發階段，目前營收來源為健康食品銷售，僅於出貨予代理商之月份認列營收，因並非每月固定出貨致使營收變動。 | ||
| 2025/9 | 0.0 | -100.0 | -100.0 | 0.26 | -26.92 | 0.13 | 0.37 | 本月健康食品銷售較去年同期減少 | ||
| 2025/8 | 0.06 | -28.84 | -54.06 | 0.26 | 6.97 | 0.13 | 0.37 | 本月健康食品銷售較去年同期減少。 | ||
| 2025/7 | 0.08 | 0.0 | 0.0 | 0.2 | 69.71 | 0.08 | 0.64 | 本月健康食品銷售較去年同期增加 | ||
| 2025/6 | 0.0 | 0.0 | 0.0 | 0.12 | 3.36 | 0.12 | 0.57 | 本期健康食品銷售較去年同期增加 | ||
| 2025/5 | 0.0 | -100.0 | -100.0 | 0.12 | 3.36 | 0.12 | 0.57 | 本月健康食品銷售較去年同期減少。 | ||
| 2025/4 | 0.12 | 0.0 | 0.0 | 0.12 | 207.91 | 0.12 | 0.57 | 本期健康食品銷售較去年同期增加。 | ||
| 2025/3 | 0.0 | 0.0 | 0.0 | 0.0 | -100.0 | 0.0 | 0 | 本期健康食品銷售較去年同期減少 | ||
| 2025/2 | 0.0 | 0.0 | -100.0 | 0.0 | -100.0 | 0.0 | 0 | 本期健康食品銷售較去年同期減少。 | ||
| 2025/1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.09 | 0.75 | 本月無健康食品收入 | ||
| 2024/12 | 0.0 | -100.0 | -100.0 | 0.44 | 14.13 | 0.09 | 0.32 | 本月健康食品銷售較去年同期減少。 | ||
| 2024/11 | 0.09 | 0.0 | 7768.06 | 0.44 | 52.15 | 0.2 | 0.15 | 本期健康食品銷售較去年同期增加。 | ||
| 2024/10 | 0.0 | -100.0 | -100.0 | 0.35 | 20.58 | 0.0 | N/A | 本月健康食品銷售較去年同期減少。 | ||
| 2024/9 | 0.11 | -8.44 | 0.0 | 0.35 | 45.97 | 0.0 | N/A | 本期健康食品銷售較去年同期增加 | ||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | |||
| N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A |
免責聲明
本網站所有資料僅供參考，如使用者依本資料交易發生交易損失需自行負責，本網站對資料內容錯誤﹑更新延誤不負任何責任。